Idursulfase for the treatment of mucopolysaccharidosis II

Author： Clarke Lorne A  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.2, 2008-02, pp. : 311-317

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical Picture and Treatment

By  

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 6, 2011-06 ,pp. : 861-866

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI

By  

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 6, 2011-06 ,pp. : 956-972

Bentham Science Publishers

Access to resources Recommend Favorite

Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Emerging Treatment Strategies

By  

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 6, 2011-06 ,pp. : 923-930

Bentham Science Publishers

Access to resources Recommend Favorite

-L-iduronidase shows long-term efficacy in the treatment of patients with mucopolysaccharidosis I

By  

Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review

By  

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 6, 2011-06 ,pp. : 931-945

Bentham Science Publishers

Access to resources Recommend Favorite